VKVladislav Yu. Kirsanov

Vladislav Yu. Kirsanov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vladislav Yu. Kirsanov has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Quantitative Assessment of TUBB3 Expression Parameters in non-Small Cell Lung Cancer Tissue at Different Stages of the Disease

    by T. A. Bogush, A. N. Grishanina, E. A. Bogush, V. Yu. Kirsanov, A. M. Scherbakov, M. A. Sventitskaya, M. Ya. Melnikov, Т. А. Богуш, А. Н. Гришанина, Е. А. Богуш, et al.

    Background . The importance of expanding the list of prognostic characteristics for stage 1 non-small cell lung cancer (NSCLC), which is characterized by the most favorable prognosis but poses a number of important tactical tasks for postoperative patient management, has been discussed in numerous studies. The aim of the study was to determine the pathogenetic and clinical significance of TUBB3 expression as a molecular marker of NSCLC aggressiveness at stage 1. Material and methods . A comparative analysis of TUBB3 expression in surgical samples of NSCLC (n = 64) at stages 1 and 3 was performed using flow cytometry-associated immunofluorescence. Primary monoclonal antibodies to TUBB3 (EP1569Y) and secondary antibodies conjugated with DyLight650 dye were used. Fluorescence was measured on a Navios flow cytometer. The number of stained cells was determined using the Kolmogorov–Smirnov test in FlowJo 10.0.8 software. Statistical analysis was performed using GraphPad Prism 6.0. Results. TUBB3 expression in stage 1 NSCLC tumors was shown to be higher than the median values for level (P = 0.000), intensity (P = 0.001), and integral index (P = 0.003) compared to stage 3 disease. For the integral index of the marker expression, the difference was nearly twofold. Conclusion . The detection of high expression of TUBB3 in NSCLC tissue at stage 1 of the disease should be considered among the prognostically unfavorable clinical and morphological characteristics of the tumor as an additional guideline for choosing optimal postoperative patient management.

  • Immunofluorescence Assessment of TUBB3 Expression in Non-Small Cell Lung Cancer Tissue by Flow Cytometry: A 50% Marker Hyperexpression Threshold for Risk Stratification in Stage I Disease

    by M. A. Sventitskaya, T. A. Bogush, A. N. Grishanina, E. A. Bogush, V. Yu. Kirsanov, A. M. Scherbakov, A. Lee, M. Ya. Melnikov

    An immunofluorescence analysis of TUBB3 expression was performed in tissue samples from patients with stage I and stage III non-small cell lung cancer (NSC

  • Comprehensive Immunophenotypic Characterization of Sarcoma Cell Cultures by Five Tumor Markers

    by T. A. Bogush, A. N. Grishanina, S. S. Dorzhieva, E. A. Bogush, A. M. Scherbakov, V. Yu. Kirsanov, E. N. Kosobokova, M. Ya. Melnikov

  • Open Access

    Diagnosis and treatment of pediatric brain tumors

    by E. O. Shebanova, A. O. Kurmanova, N. V. Sevyan, E. V. Prozorenko, V. Yu. Kirsanov

    Brain tumors are the most common solid tumors in children and are associated with high mortality. The most common childhood brain tumors are grouped as low­grade gliomas, high grade gliomas, ependymomas, and embryonal tumors, according to the World Health Organization (WHO). Advances in molecular genetics have led to a shift from pure histopathological diagnosis to integrated diagnosis. For the first time, these new criteria were included in the WHO classification published in 2016 and has been further updated in the 2021 edition. Integrated diagnosis is based on molecular genomic similarities of the tumor subclasses, and it can better explain the differences in clinical courses of previously histopathologically identical entities. Important advances have also been made in pediatric neuro­oncology. A growing understanding of the molecular­genetic background of tumorigenesis has improved the diagnostic accuracy. Re­stratification of treatment protocols and the development of targeted therapies will significantly affect overall survival and quality of life. For some pediatric tumors, these advances have significantly improved therapeutic management and prognosis in certain tumor subgroups. Some therapeutic approaches also have serious long­term consequences. Therefore, optimized treatments are greatly needed.

  • Open Access

    Efficacy of total neoadjuvant chemotherapy in the FLOT regimen in patients with locally advanced gastric and gastroesophageal junction: results of a phase II study

    by A. Yu. Anokhin, P. V. Kononets, D. Yu. Kanner, D. L. Stroyakovsky, A. O. Shveykin, A. E. Kalinin, V. Yu. Kirsanov, A. S. Tyulandina

    Background. The established approach notably improving the therapeutic outcomes for locally advanced gastric cancer and gastroesophageal junction cancer, presently entails the amalgamation of perioperative chemotherapy aligned with the FLOT protocol and surgical intervention. However, this approach harbors limitations, as only half of the patient cohort successfully completes the entire prescribed course of drug therapy. The potential solution to this problem lies in the complete transfer of the chemotherapy volume to the preoperative period and the execution of total neoadjuvant chemotherapy with FLOT regimen.Aim. Aim is to conduct a comparative assessment of the efficacy and safety between total neoadjuvant and perioperative chemotherapy with FLOT regimen for patients with locally advanced gastric cancer and gastroesophageal junction cancer.Materials and methods. In a retrospective study we enrolled patients with histologically confirmed locally advanced gastric cancer and gastroesophageal junction cancer meeting clinical stage criteria T2–4 and N0–3, without of distant metastases, treated between 2014 and 2020 at Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” оf the Ministry of Health of the Russian Federation and Moscow City Oncologic Hospital No. 62 Department of Healthcare of Moscow. Participants in the control group underwent 8 courses of perioperative chemotherapy (4 preoperatively and 4 postoperatively), while those in the experimental group received 8 courses of total neoadjuvant chemotherapy. Both groups received drug therapy according to the FLOT protocol: 5-fluorouracil 2600 mg/m2 , intravenous drip, over 24 hours, leucovorin 200 mg/m2 , intravenous drip, oxaliplatin 85 mg/m2 , intravenous drip, docetaxel 50 mg/m2 , intravenous drip, on day 1, with a 14-day intercourse interval. The primary endpoint was one-year progression-free survival.Results. In the study included 187 patients. Participants were divided into two groups: 95 in the total neoadjuvant chemotherapy group and 92 in the perioperative chemotherapy group. The one-year progression-free survival was higher in the total neoadjuvant chemotherapy group at 79 %, compared to 68 % in the perioperative chemotherapy group (HR 0.54, 95 % confidence interval 0.32–0.9, p = 0.02). Median disease-free survival was 27.2 and 19.5 months in the neoadjuvant and perioperative chemotherapy groups, respectively. The tolerability of the entire planned drug treatment regimen was superior in the total neoadjuvant chemotherapy group, reaching 88.4 %, as opposed to 57.6 % in the perioperative chemotherapy group (p = 0.0001).Conclusion. Among patients with locally advanced gastric cancer and gastroesophageal junction cancer, the application of total neoadjuvant chemotherapy according to the FLOT protocol, administered over 8 courses, demonstrated enhanced one-year progression-free survival and improved tolerability of the entire planned treatment regimen.


  • Open Access

    Modern possibilities for the correction of menopausal symptoms in patients with breast cancer, depending on the molecular biological characteristics of the tumor (literature review)

    by I. V. Vysotskaya, E. A. Kim, M. V. Geletko, F. E. Misrikhanova, V. Yu. Kirsanov

    Breast cancer (BC) ranks first in cancer incidence among women. For successful treatment of BC, depending on the molecular type and stage of the disease, chemotherapy is used, the side effects of which are manifested by menopausal symptoms, sexual dysfunction, and depressive states. However, not all patients after BC receive appropriate therapy for menopausal symptoms, what significantly worsens their quality of life. One of the symptoms that brings the most severe discomfort is the vasomotor symptom, a form of temperature dysfunction with peripheral vasodilation and increased cutaneous blood flow that results in increased heat loss. There are several types of drugs that are used to prevent menopausal symptoms in patients taking endocrine chemotherapy, many of which are in the experimental phase of development. In this review, we will try to identify proven effective and safe methods for correcting menopausal symptoms in women who underwent chemotherapy and endocrine therapy for BC.

  • Open Access

    Discussion article: do we understand the role of local treatments after oligoprogression of ovarian cancer on PARP inhibitors?

    by A. A. Rumyantsev, A. K. Zarenkova, V. Yu. Kirsanov

    The development of poly(ADP‐ribose) polymerase (PARP) inhibitors has been the most significant breakthrough in the treatment of advanced ovarian cancer over recent decades, with olaparib being the first drug of this class. The drug showed its efficacy at many stages of the treatment of various oncological diseases, but its maximum clinical efficacy is demonstrated in the initial treatment of BRCA-associated or HRD-positive ovarian cancer. In the phase III SOLO1 (n = 391) and PAOLA-1 (n = 806) clinical trials, treatment with olaparib reduced the relative risk of disease progression by 67% and 59%, and the risk of death by 45% and 38%, respectively. At the same time, the treatment of patients with disease progression after therapy with PARP inhibitors causes reasonable concerns in clinicians, which is associated with many aspects, primarily with the lack of individually developed approaches to the management of this category of patients. This discussion article through the example of the treatment of a particular patient allows to summarize the current data on the features of the tumour process after disease progression on PARP inhibitors and possible ways to resolve the issue of drug resistance in such patients. In the clinical case under discussion, the maintenance therapy with olaparib after combination treatment in a 50-year-old woman with metachronous multiple primary BRCA-associated malignancies (breast cancer in 2005, ovarian cancer in 2018) allowed to achieve a 2-year cancer remission, after which the oligoprogression of ovarian cancer was observed. PET-CT showed a left iliac lymph node metastasis without other progressive manifestations of the disease, after which a left laparoscopic iliac lymphadenectomy was performed, and the olaparib therapy was continued until progression or intolerable toxicity. The duration of olaparib therapy from the date when the local treatment was performed is 23 months as of this writing. The article states the detailed rationale behind choosing the non-standard management and presents the results of recent studies that support the decisions made.

  • Open Access

    Molecular effects of Mastodynon: realities and prospects for cancer prevention

    by I. V. Vysotskaya, E. A. Kim, V. Yu. Kirsanov, S. B. Polikarpova, V. E. Ponomarev

    The article presents updated data concerning the molecular mechanisms of influence of the well-known in clinical practice drug Mastodynon. The paper provides evidence of a significant effect of the compounds containing in its composition on the cell lines of a number of malignant neoplasms: breast cancer, hepatocellular carcinoma, leukemia and others. The data obtained are extremely attractive in the perspective of using the drug as a preventive agent.


  • Open Access

    BRAF-mutant melanoma of the skin during pregnancy with dichorionic diamniotic twins. Clinical case

    by M. M. Davydov, P. A. Zeynalova, A. A. Fedenko, D. A. Chekiny, E. K. Ibragimov, A. A. Filimonov, O. V. Sinitsyna, E. A. Bogush, M. A. Chekalova, G. F. Allakhverdieva, et al.

    Per the majority of authors, melanoma is the most common tumor diagnosed during pregnancy (31 % of all malignant neoplasms). In approximately 1/3 of women melanoma developed in child-bearing age is diagnosed during pregnancy or in the postpartum period. However, only some retrospective studies analyzed the effect of pregnancy on melanoma development, and conclusive data on development, progression and treatment of BRAF-mutant melanoma is lacking. In this subpopulation of patients, BRAF status supposedly can negatively affect disease outcome irrespective of treatment methods.The article presents a clinical case of recurrence of melanoma with the BRAF V600E mutation during pregnancy. The patient underwent lymph node dissection during pregnancy prolongation, after labor she received antitumor drug therapy with МЕК and ВRAF inhibitors. Melanoma recurrence during pregnancy did not worsen treatment outcomes for the mother and embryo.

  • Open Access

    Lesions of the breast with uncertain malignant potential

    by I. V. Vуsotskaya, I. A. Gladilina, V. Yu. Kirsanov, Н. В. Понедельникова, E. A. Kim, V. E. Ponomarev

    The article deals with a peculiar group of breast diseases, which belongs to the B3 category according to the BI-RADS classification, the so-called lesions with undefined malignant potential. The basic information concerning their biological behavior and modern tactical approaches to the management of patients with similar changes in the mammary gland are presented. The possibility of conservative management, as well as the minimization of surgical aid, in cases of indications for it, up to vacuum aspiration biopsy is being considered. In addition, the significance of these diseases for the subsequent development of pre-invasive and infiltrative cancer is discussed.